Evidence map›Paper›PMID 26783074›Full record

ArticleEuropean journal of immunology2016

Too much of a good thing: Sustained type 1 interferon signaling limits humoral responses to secondary viral infection.

John R Teijaro

Open access · bronzeAbstract read
In one paragraph

Article in European journal of immunology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Trial
  2. Article
  3. CSF-1-induced DC-SIGNReproductive biology and endocrinology : RB&E · 2022
    Article
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

John R TeijaroDepartment of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA, USA.
Scripps Research Institute · US

Funding

IL-27 elicited antibodies: A novel means to control persistent Arenavirus infectionR01AI118862 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI TEIJARO, JOHN ROSS · 2016 to 2020
$2.4M
Novel Strategies for Controlling Persistent Viral InfectionR01AI123210 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI TEIJARO, JOHN ROSS · 2016 to 2019
$1.9M
The Role of IL-27 in Controlling Persistent Viral InfectionR56AI104898 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI TEIJARO, JOHN ROSS · 2014 to 2014
$474k
NIAID NIH HHS 1R56AI104898-01A1NIAID NIH HHS R01 AI118862NIAID NIH HHS R01 AI123210NIAID NIH HHS R56 AI104898
6 · The paper itself

Abstract

The induction of a pan-immunosuppressive state is a central feature of persistent viral infections. Over the past decade, multiple pathways have been identified that contribute to immune suppression. Recently, it was revealed that aberrant or sustained type 1 interferon (IFN-I) production or signaling is a central contributor to immune suppression elicited during persistent viral infection. In this issue, Honke et al. [Eur. J. Immunol. 2016. 46: 372-380] identify that IFN-I signaling promotes an immune suppressive state during persistent lymphocytic choriomeningitis virus infection by inhibiting enforced virus replication in CD169(+) macrophages. The authors demonstrate that mice infected with a persistent strain of lymphocytic choriomeningitis virus have blunted humoral immune responses to a superinfecting vesicular stomatitis virus infection. The absence of virus replication in CD169(+) macrophages was not due to antiviral CD8(+) T cell-mediated killing of CD169(+) macrophages, but required sustained IFN-I responses. In turn, reduction in vesicular stomatitis virus replication in CD169(+) macrophages resulted in a reduction in antigen production, which is necessary for generating optimal humoral responses. This study highlights a novel mechanism by which IFN-I signaling promotes an immune suppressive state during persistent viral infection.

Indexed as

AnimalsAntibodies, ViralAntigen PresentationAntigens, ViralHumansImmunity, HumoralImmunosuppression TherapyInterferon Type ILymphocytic ChoriomeningitisLymphocytic choriomeningitis virusMacrophagesMiceSignal TransductionSuperinfectionVesicular StomatitisVesiculovirusAntibodies, ViralAntigens, ViralInterferon Type IChronic infectionLymphocytic choriomeningitis virusMacrophagesType I InterferonVesicular stomatitis virus

Identifiers

PMID26783074
PMCPMC5113021
OpenAlexW2290885500

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.